Hyperuricemia, Metabolically Healthy Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease
Conditions
Brief summary
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.
Interventions
None listed
Sponsors
Ningbo No. 1 Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024; 2. Aged 18 years or older at baseline; 3. Completed an abdominal ultrasound examination during the health check-up.
Exclusion criteria
1. Underweight status at baseline, defined as BMI \< 18.5 kg/m² ； 2. Missing data on height, weight, or components of the metabolic syndrome ; 3. Baseline diagnosis of MASLD or any other liver diseases 4. Baseline diagnosis of hyperuricemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of MASLD and Hyperuricemia | 7 years | through study completion |
Countries
China
Outcome results
None listed